Introduction
The global schizophrenia market will continue to grow until 2010, when revenues will reach $3.8 billion. However, despite the launch of numerous pipeline schizophrenia drugs, the market will begin to decline thereafter owing to the US launch of generic risperidone in 2007, followed by generic versions of olanzapine, quetiapine and ziprasidone from 2011 onwards.
Scope of this report
- Detailed pipeline analysis for key products in development for schizophrenia, plus drug sales forecasts to 2015
- Overview of patient potential, segmentation by indication and unmet needs in schizophrenia across the US, EU and Japan
- Benchmarking of key product and company attractiveness of late-phase pipeline products
- Detailed clinical trial information and opinions from key thought leaders
Research and analysis highlights
By 2015, prospective players can expect to face stiff competition from numerous generic atypical antipsychotics. Product differentiation through improved treatment of negative or cognitive symptoms, partial responders, as well as improved tolerability, and demonstration of cost-effectiveness are essential.
Current schizophrenia drug manufacturers are taking measures to buffer the erosion of their products by generics over the forecast period. Of the current players, Datamonitor forecasts that only Pfizer will maintain a strong schizophrenia franchise after the genericization of its marketed drug, with the remaining franchises expected to decline.
The potential of Organon/Pfizer's asenapine in treating negative symptoms will be a key therapeutic and commercial advantage, with the drug forecast to be the leading market entrant in terms of value by 2015. Lundbeck/Solvay/Wyeth's bifeprunox's will become the second highest new entrant in terms of value by 2015.
Key reasons to read this report
- Understand unmet needs in the schizophrenia market based on key opinion leader comments regarding both currently marketed and pipeline products
- Benchmark key late-stage schizophrenia compounds against current market leaders
- Assess the global sales forecasts of late-stage pipeline drugs for schizophrenia and examine their clinical and commercial potential
| 
View Cart
